Aberrantly methylated DNA as a biomarker in breast cancer

International Journal of Biological Markers

Volumn 28, Issue 2, 2013, Pages 141-150

  Kristiansen, Søren ^a   Jørgensen, Lars M ^a   Guldberg, Per ^b   Sölétormos, György ^a  

^a HILLERØD HOSPITAL   (Denmark)

^b DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

Author keywords

Breast cancer; DNA biomarker; DNA methylation; Epigenetic; Promoter methylation

Indexed keywords

ANTHRACYCLINE; APC PROTEIN; BIOLOGICAL MARKER; BRCA1 PROTEIN; CCN PROTEIN; CYCLIN D2; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLOPHOSPHAMIDE; DEATH ASSOCIATED PROTEIN KINASE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; GLUTATHIONE TRANSFERASE P1; METHOTREXATE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PACLITAXEL; PROGESTERONE RECEPTOR; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; RETINOID RELATED ORPHAN RECEPTOR BETA; TAMOXIFEN; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TRANSCRIPTION FACTOR TWIST; TRASTUZUMAB; UVOMORULIN;

ADJUVANT THERAPY; ARTICLE; ATAXIA TELANGIECTASIA; BREAST CANCER; CANCER GROWTH; CANCER PROGNOSIS; CARCINOGENESIS; CELL CYCLE REGULATION; CONTROLLED STUDY; DNA METHYLATION; ECHOGRAPHY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MAMMOGRAPHY; METASTASIS; NIPPLE ASPIRATION; PAGET NIPPLE DISEASE; POLYMERASE CHAIN REACTION; TUMOR BIOPSY;

BREAST NEOPLASMS; CARCINOGENESIS; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; HUMANS; PROGNOSIS; PROMOTER REGIONS, GENETIC; TUMOR MARKERS, BIOLOGICAL;

EID: 84879724429     PISSN: 03936155     EISSN: 17246008     Source Type: Journal    
DOI: 10.5301/jbm.5000009     Document Type: Article

References (77)

1. The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490: 61-70.
2. Gage M, Wattendorf D, Henry LR. Translational advances regarding hereditary breast cancer syndromes. J Surg Oncol 2012; 105: 444-51.
3. Antill YC, Mitchell G, Johnson SA, et al. Gene methylation in breast ductal fluid from BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev 2010; 19: 265-74.
4. Dedeurwaerder S, Desmedt C, Calonne E, et al. DNA methylation profiling reveals a predominant immune component in breast cancers. EMBO Mol Med 2011; 3: 726-41.
5. Jovanovic J, Ronneberg JA, Tost J, Kristensen V. The epigenetics of breast cancer. Mol Oncol 2010; 4: 242-54.
6. Van De Voorde L, Speeckaert R, Van Gestel D, et al. DNA methylation-based biomarkers in serum of patients with breast cancer. Mutat Res 2012; 751: 304-25.
7. Dulaimi E, Hillinck J, Ibanez de Caceres I, Al-Saleem T, Cairns P. Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients. Clin Cancer Res 2004; 10: 6189-93.
8. Tan SH, Ida H, Lau QC, et al. Detection of promoter hypermethylation in serum samples of cancer patients by methylation-specific polymerase chain reaction for tumour suppressor genes including RUNX3. Oncol Rep 2007; 18: 1225-30.
9. Martinez-Galan J, Torres B, Del Moral R, et al. Quantitative detection of methylated ESR1 and 14-3-3-sigma gene promoters in serum as candidate biomarkers for diagnosis of breast cancer and evaluation of treatment efficacy. Cancer Biol Ther 2008; 7: 958-65.
10. Jing F, Yuping W, Yong C, et al. CpG island methylator phenotype of multigene in serum of sporadic breast carcinoma. Tumour Biol 2010; 31: 321-31.
11. Hoque MO, Feng Q, Toure P, et al. Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer. J Clin Oncol 2006; 24: 4262-9.
12. Hu XC, Wong IH, Chow LW. Tumor-derived aberrant methylation in plasma of invasive ductal breast cancer patients: Clinical implications. Oncol Rep 2003; 10: 1811-5.
13. Radpour R, Barekati Z, Kohler C, et al. Hypermethylation of tumor suppressor genes involved in critical regulatory pathways for developing a blood-based test in breast cancer. PLoS One 2011; 6: 16080.
14. Mirza S, Sharma G, Parshad R, Srivastava A, Gupta SD, Ralhan R. Clinical significance of stratifin, ERalpha and PR promoter methylation in tumor and serum DNA in indian breast cancer patients. Clin Biochem 2010; 43: 380-6.
15. Pu RT, Laitala LE, Alli PM, Fackler MJ, Sukumar S, Clark DP. Methylation profiling of benign and malignant breast lesions and its application to cytopathology. Mod Pathol 2003; 16: 1095-101.
16. Jeronimo C, Costa I, Martins MC, et al. Detection of gene promoter hypermethylation in fine needle washings from breast lesions. Clin Cancer Res 2003; 15; 9: 3413-7.
17. Zhu W, Qin W, Hewett JE, Sauter ER. Quantitative evaluation of DNA hypermethylation in malignant and benign breast tissue and fluids. Int J Cancer 2010; 126: 474-82.
18. Krassenstein R, Sauter E, Dulaimi E, et al. Detection of breast cancer in nipple aspirate fluid by CpG island hypermethylation. Clin Cancer Res 2004; 10: 28-32.
19. Evron E, Dooley WC, Umbricht CB, et al. Detection of breast cancer cells in ductal lavage fluid by methylationspecific PCR. Lancet 2001; 357: 1335-6.
20. Fackler MJ, Malone K, Zhang Z, et al. Quantitative multiplex methylation-specific PCR analysis doubles detection of tumor cells in breast ductal fluid. Clin Cancer Res 2006; 12: 3306-10.
21. Brennan K, Garcia-Closas M, Orr N, et al. Intragenic ATM methylation in peripheral blood DNA as a biomarker of breast cancer risk. Cancer Res 2012; 72: 2304-13.
22. Xu X, Gammon MD, Hernandez-Vargas H, et al. DNA methylation in peripheral blood measured by LUMA is associated with breast cancer in a population-based study. FASEB J 2012; 26: 2657-66.
23. Evron E, Umbricht CB, Korz D, et al. Loss of cyclin D2 expression in the majority of breast cancers is associated with promoter hypermethylation. Cancer Res 2001; 61: 2782-7.
24. Silva J, Silva JM, Dominguez G, et al. Concomitant expression of p16INK4a and p14ARF in primary breast cancer and analysis of inactivation mechanisms. J Pathol 2003; 199: 289-97.
25. Prasad CP, Mirza S, Sharma G, et al. Epigenetic alterations of CDH1 and APC genes: Relationship with activation of Wnt/beta-catenin pathway in invasive ductal carcinoma of breast. Life Sci 2008; 83: 318-25.
26. Sarrio D, Moreno-Bueno G, Hardisson D, et al. Epigenetic and genetic alterations of APC and CDH1 genes in lobular breast cancer: relationships with abnormal E-cadherin and catenin expression and microsatellite instability. Int J Cancer 2003; 106: 208-15.
27. Zou D, Yoon HS, Perez D, Weeks RJ, Guilford P, Humar B. Epigenetic silencing in non-neoplastic epithelia identifies E-cadherin (CDH1) as a target for chemoprevention of lobular neoplasia. J Pathol 2009; 218: 265-72.
28. Hu XC, Loo WT, Chow LW. E-cadherin promoter methylation can regulate its expression in invasive ductal breast cancer tissue in Chinese woman. Life Sci 2002; 71: 1397-404.
29. Graff JR, Herman JG, Lapidus RG, et al. E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res 1995; 55: 5195-9.
30. Toyooka KO, Toyooka S, Virmani AK, et al. Loss of expression and aberrant methylation of the CDH13 (H-cadherin) gene in breast and lung carcinomas. Cancer Res 2001; 61: 4556-60.
31. Jin Z, Tamura G, Tsuchiya T, et al. Adenomatous polyposis coli (APC) gene promoter hypermethylation in primary breast cancers. Br J Cancer 2001; 85: 69-73.
32. Fackler MJ, McVeigh M, Evron E, et al. DNA methylation of RASSF1A, HIN-1, RAR-beta, cyclin D2 and twist in in situ and invasive lobular breast carcinoma. Int J Cancer 2003; 107: 970-5.
33. Burbee DG, Forgacs E, Zochbauer-Muller S, et al. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst 2001; 93: 691-9.
34. Shinozaki M, Hoon DS, Giuliano AE, et al. Distinct hypermethylation profile of primary breast cancer is associated with sentinel lymph node metastasis. Clin Cancer Res 2005; 11: 2156-62.
35. Caldeira JR, Prando EC, Quevedo FC, Neto FA, Rainho CA, Rogatto SR. CDH1 promoter hypermethylation and E-cadherin protein expression in infiltrating breast cancer. BMC Cancer 2006; 6: 48.
36. Feng W, Shen L, Wen S, et al. Correlation between CpG methylation profiles and hormone receptor status in breast cancers. Breast Cancer Res 2007; 9: R57.
37. Sunami E, Shinozaki M, Sim MS, et al. Estrogen receptor and HER2/neu status affect epigenetic differences of tumorrelated genes in primary breast tumors. Breast Cancer Res 2008; 10: R46.
38. Jing F, Jun L, Yong Z, et al. Multigene methylation in serum of sporadic Chinese female breast cancer patients as a prognostic biomarker. Oncology 2008; 75: 60-6.
39. Matuschek C, Bolke E, Lammering G, et al. Methylated APC and GSTP1 genes in serum DNA correlate with the presence of circulating blood tumor cells and are associated with a more aggressive and advanced breast cancer disease. Eur J Med Res 2010; 26: 15 277-86.
40. Hoque MO, Prencipe M, Poeta ML, et al. Changes in CpG islands promoter methylation patterns during ductal breast carcinoma progression. Cancer Epidemiol Biomarkers Prev 2009; 18: 2694-700.
41. Nass SJ, Herman JG, Gabrielson E, et al. Aberrant methylation of the estrogen receptor and E-cadherin 5' CpG islands increases with malignant progression in human breast cancer. Cancer Res 2000; 60: 4346-8.
42. Park SY, Kwon HJ, Lee HE, et al. Promoter CpG island hypermethylation during breast cancer progression. Virchows Arch 2011; 458: 73-84.
43. Widschwendter M, Berger J, Hermann M, et al. Methylation and silencing of the retinoic acid receptor-beta2 gene in breast cancer. J Natl Cancer Inst 2000; 92: 826-32.
44. Lehmann U, Langer F, Feist H, Glockner S, Hasemeier B, Kreipe H. Quantitative assessment of promoter hypermethylation during breast cancer development. Am J Pathol 2002; 160: 605-12.
45. Sharma G, Mirza S, Yang YH, et al. Prognostic relevance of promoter hypermethylation of multiple genes in breast cancer patients. Cell Oncol 2009; 31: 487-500.
46. Muller HM, Fiegl H, Widschwendter A, Widschwendter M. Prognostic DNA methylation marker in serum of cancer patients. Ann N Y Acad Sci 2004; 1022: 44-9.
47. Martins AT, Monteiro P, Ramalho-Carvalho J, et al. High RASSF1A promoter methylation levels are predictive of poor prognosis in fine-needle aspirate washings of breast cancer lesions. Breast Cancer Res Treat 2011; 129: 1-9.
48. Nimmrich I, Sieuwerts AM, Meijer-van Gelder ME, et al. DNA hypermethylation of PITX2 is a marker of poor prognosis in untreated lymph node-negative hormone receptorpositive breast cancer patients. Breast Cancer Res Treat 2008; 111: 429-37.
49. Arai T, Miyoshi Y, Kim SJ, Taguchi T, Tamaki Y, Noguchi S. Association of GSTP1 CpG islands hypermethylation with poor prognosis in human breast cancers. Breast Cancer Res Treat 2006; 100: 169-76.
50. Van der Auwera I, Elst HJ, Van Laere SJ, et al. The presence of circulating total DNA and methylated genes is associated with circulating tumour cells in blood from breast cancer patients. Br J Cancer 2009; 100: 1277-86.
51. Mehrotra J, Vali M, McVeigh M, et al. Very high frequency of hypermethylated genes in breast cancer metastasis to the bone, brain, and lung. Clin Cancer Res 2004; 10: 3104-9.
52. Zurita M, Lara PC, del Moral R, et al. Hypermethylated 14-3-3-sigma and ESR1 gene promoters in serum as candidate biomarkers for the diagnosis and treatment efficacy of breast cancer metastasis. BMC Cancer 2010; 10: 217.
53. Gobel G, Auer D, Gaugg I, et al. Prognostic significance of methylated RASSF1A and PITX2 genes in blood-and bone marrow plasma of breast cancer patients. Breast Cancer Res Treat 2011; 130: 109-17.
54. Widschwendter M, Siegmund KD, Muller HM, et al. Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. Cancer Res 2004; 64: 3807-13.
55. Fiegl H, Millinger S, Mueller-Holzner E, et al. Circulating tumor-specific DNA: A marker for monitoring efficacy of adjuvant therapy in cancer patients. Cancer Res 2005;15; 65: 1141-5.
56. Liggett TE, Melnikov AA, Marks JR, Levenson VV. Methylation patterns in cell-free plasma DNA reflect removal of the primary tumor and drug treatment of breast cancer patients. Int J Cancer 2011; 128: 492-9.
57. Martens JW, Nimmrich I, Koenig T, et al. Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer. Cancer Res 2005; 65: 4101-17.
58. Iorns E, Turner NC, Elliott R, et al. Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer. Cancer Cell 2008; 13: 91-104.
59. Maier S, Nimmrich I, Koenig T, et al. DNA-methylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients-technical and clinical validation in a multi-centre setting in collaboration with the European organisation for research and treatment of cancer (EORTC) PathoBiology group. Eur J Cancer 2007; 43: 1679-86.
60. Hartmann O, Spyratos F, Harbeck N, et al. DNA methylation markers predict outcome in node-positive, estrogen receptor-positive breast cancer with adjuvant anthracyclinebased chemotherapy. Clin Cancer Res 2009; 15: 315-23.
61. Dietrich D, Krispin M, Dietrich J, et al. CDO1 promoter methylation is a biomarker for outcome prediction of anthracycline treated, estrogen receptor-positive, lymph nodepositive breast cancer patients. BMC Cancer 2010; 10: 247.
62. Dejeux E, Ronneberg JA, Solvang H, et al. DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response. Mol Cancer 2010; 9: 68.
63. Arai T, Miyoshi Y, Kim SJ, et al. Association of GSTP1 expression with resistance to docetaxel and paclitaxel in human breast cancers. Eur J Surg Oncol 2008; 34: 734-8.
64. Fumagalli C, Pruneri G, Possanzini P, et al. Methylation of O (6)-methylguanine-DNA methyltransferase (MGMT) promoter gene in triple-negative breast cancer patients. Breast Cancer Res Treat 2012; 134: 31-7.
65. Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical responseof gliomas to alkylating agents. N Engl J Med 2000; 343: 1350-4.
66. Esteller M, Herman JG. Generating mutations but providing chemosensitivity: The role of O6-methylguanine DNA methyltransferase in human cancer. Oncogene 2004; 23: 1-8.
67. Sharma G, Mirza S, Parshad R, Gupta SD, Ralhan R. DNA methylation of circulating DNA: A marker for monitoring efficacy of neoadjuvant chemotherapy in breast cancer patients. Tumour Biol 2012; 33: 1837-43.
68. Avraham A, Uhlmann R, Shperber A, et al. Serum DNA methylation for monitoring response to neoadjuvant chemotherapy in breast cancer patients. Int J Cancer 2012; 131: E1166-72.
69. Söletormos G, Duffy MJ, Hayes DF, et al. Design of Tumor Biomarker Trials: A proposal by the European group on tumor markers. Clin Chem 2013; 59: 52-9.
70. Petersen PH, Soletormos G, Pedersen MF, Lund F. Interpretation of increments in serial tumour biomarker concentrations depends on the distance of the baseline concentration from the cut-off. Clin Chem Lab Med 2011; 49: 303-10.
71. Petersen PH, Sandberg S, Iglesias N, et al. Likelihood-ratio and odds applied to monitoring of patients as a supplement to reference change value (RCV). Clin Chem Lab Med 2008; 46: 157-64.
72. Jing F, Zhang J, Tao J, et al. Hypermethylation of tumor suppressor genes BRCA1, p16 and 14-3-3 sigma in serum of sporadic breast cancer patients. Onkologie 2007; 30: 14-9.
73. Shukla S, Mirza S, Sharma G, Parshad R, Gupta SD, Ralhan R. Detection of RASSF1A and RARbeta hypermethylation in serum DNA from breast cancer patients. Epigenetics 2006; 1: 88-93.
74. Taback B, Giuliano AE, Lai R, et al. Epigenetic analysis of body fluids and tumor tissues: Application of a comprehensive molecular assessment for early-stage breast cancer patients. Ann N Y Acad Sci 2006; 1075: 211-21.
75. Sharma G, Mirza S, Prasad CP, Srivastava A, Gupta SD, Ralhan R. Promoter hypermethylation of p16INK4A, p14ARF, CyclinD2 and Slit2 in serum and tumor DNA from breast cancer patients. Life Sci 2007; 80: 1873-81.
76. Mirza S, Sharma G, Prasad CP, et al. Promoter hypermethylation of TMS1, BRCA1, ERalpha and PRB in serum and tumor DNA of invasive ductal breast carcinoma patients. Life Sci 2007; 81: 280-7.
77. Sharma G, Mirza S, Parshad R, et al. Clinical significance of promoter hypermethylation of DNA repair genes in tumor and serum DNA in invasive ductal breast carcinoma patients. Life Sci 2010; 87: 83-91.